EFFECT OF CERTOLIZUMAB PEGOL ON WORKPLACE AND HOUSEHOLD PRODUCTIVITY IN US PATIENTS WITH RHEUMATOID ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE- RESULTS FROM THE PREDICT STUDY
Author(s)
Kavanaugh A1, Mease PJ2, Strand V3, Purcaru O4, Curtis JR5
1UCSD, San Diego, CA, USA, 2Swedish Medical Center and University of Washington, Seattle, WA, USA, 3Biopharmaceutical Consultant, Portola Valley, CA, USA, 4UCB Pharma, Brussels, Belgium, 5University of Alabama at Birmingham, Birmingham, AL, USA
OBJECTIVES: To investigate the effect of CZP treatment on workplace and household productivity and social participation in US RA pts with and without prior anti-TNF exposure in the PREDICT trial (NCT01255761). METHODS: Pts received CZP standard dosing regimen (400mg at Wks 0, 2, 4 [loading dose], then 200mg Q2W). The arthritis-specific Work Productivity Survey (WPS; administered Q4W until Wk24, then Q8W) assessed the impact of CZP on workplace and household productivity, stratified by pts with (A) and without (B) prior anti-TNF exposure. Mean WPS responses (LOCF) are summarized over 52 wks RESULTS: CONCLUSIONS: In RA pts initiating CZP, there were similar improvements between those with and without prior anti-TNF exposure in workplace, household productivity and social participation. These improvements were observed as early as Wk4 and maintained through Wk52.
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PMS66
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Musculoskeletal Disorders